CHABIOTECH CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17,190 KRW | +0.06% |
|
+5.46% | -12.25% |
| Jan. 08 | CHA Biotech to Partner with Subsidiary to Advance NK Cell Therapy | MT |
| 2023 | CHA Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| Sales 2022 | 845B 615M | Sales 2023 | 954B 694M | Capitalization | 1,103B 803M |
|---|---|---|---|---|---|
| Net income 2022 | -47.54B -34.61M | Net income 2023 | -8.43B -6.14M | EV / Sales 2022 | 1.13 x |
| Net Debt 2022 | 225B 164M | Net Debt 2023 | 228B 166M | EV / Sales 2023 | 1.4 x |
| P/E ratio 2022 |
-15.4
x | P/E ratio 2023 |
-112
x | Employees | 312 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 69.17% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.06% | ||
| 1 week | +5.46% | ||
| Current month | -11.66% | ||
| 1 month | -9.43% | ||
| 3 months | -1.72% | ||
| 6 months | +3.18% | ||
| Current year | -12.25% |
1 week
16 250.00
17 400.00
1 month
16 120.0021 000.00
Current year
16 120.0021 000.00
1 year
11 790.0023 100.00
3 years
11 790.0031 100.00
5 years
10 000.0031 100.00
10 years
10 000.0042 800.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sang-Hoon Oh
CEO | Chief Executive Officer | 60 | 19-02-28 |
Dong-Joon Lee
DFI | Director of Finance/CFO | 53 | 19-03-31 |
Jong-Guk Song
PSD | President | 63 | 05-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sang-kyu Lee
BRD | Director/Board Member | 72 | - |
Jong-Guk Song
PSD | President | 63 | 05-12-31 |
Joong-Ho Kim
BRD | Director/Board Member | 80 | 08-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 2 M€ | -.--% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +0.68% | - | |
| 0.00% | 34 M€ | +2.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 17,190 | +0.06% | 123,333 |
| 24-04-23 | 17,180 | +0.82% | 155,613 |
| 24-04-22 | 17,040 | +3.21% | 198,414 |
| 24-04-19 | 16,510 | -2.31% | 226,993 |
| 24-04-18 | 16,900 | +3.68% | 414,653 |
End-of-day quote Korea S.E., April 23, 2024
More quotes
Chabiotech Co.,Ltd. is a Korea-based company mainly engaged in the bio business. Along with its subsidiaries, the Company operates its business through two segments: bio segment and optical segment. Its bio segment engages in the provision of medical services; development of stem cells and cell therapy products; production of cosmetics and cosmetic raw materials; distribution of medical devices and others, as well as cord blood storage, health care services and others. Its optical segment engages in the manufacture of optical lenses, optical modules and other parts, which are used in mobile phone cameras.
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -12.25% | 704M | |
| +4.09% | 43.84B | |
| +46.85% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- A085660 Stock
